104079172 : I attended the pre-symposium analyst presentation of just now and the results of the current 6 month in phase trial for Olema's palazestrant is extremely promising pre the big upcoming trial in 2025

104079172 : The analyst presentation today of the same data that will be presented at the symposium was extremely good. Good chance the stock price will go up well in the next few days

104079172 : I am surprised that the share price is currently not moving up much to be honest

Trytosaveabit OP 104079172 : Just no volume!

104079172 : Yes indeed. I suspect that most retail investors have their attention elsewhere. And the institutions are in it for the long haul hence the volume is really bad. This company will do well in 12 months. High chance that Novartis might acquire it given that it doesn't currently have a similar promising drug in its own pipeline (it's own type has no news for a long time and Olema seems to be clever enough to partner with Novartis to do a ribo combo with Palazestrant in its ongoing phase trials)